Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines.
The Details: Issued on September 24, the patent entitled 'Pharmaceutical Composition for Treating Migraine' is anticipated to provide protection into 2036.
This comes after the company launched a campaign called 'Does Your Migraine Pill Work Every Time?' with the goal of informing healthcare providers and consumers about the advantages of non-oral migraine medications.
How To Buy Tonix Pharmaceuticals Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Tonix Pharmaceuticals (NASDAQ:TNXP)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
TNXP Price Action: At the time of writing, Tonix shares are trading 17.2% higher at 16 cents, according to data from Benzinga Pro.
Image: Akava Photo from Pixabay
